NanoString Says New PAM50 Studies Confirm Assay's Clinical Validity

The quintet of studies, presented at the American Society of Clinical Oncology annual meeting last week, could help support NanoString's diagnostic ambitions.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories